Analysis for MRNA

📈 Growth & Financial Trajectory

The eight-quarter sequence shows a steep revenue decline from about $1.86B in 2024-Q3 to about $0.15B in 2026-Q2, a roughly 92% drop. Net income remains negative across the period, with a brief positive blip of about $13M in 2025-Q3, but the trend remains weak. Operating cash flow is negative in most quarters, indicating ongoing cash burn despite intermittent financing/investing inflows.

💰 Margins & Cash Flow

Gross profit oscillates; some quarters show high margins while others are negative. The data show volatile margins (e.g., positive gross profit in earlier quarters vs negative in Q4 2024), suggesting weak operating leverage. Operating cash flow is consistently negative across the window (e.g., Q1 2026 and Q2 2026), with occasional cash contributions from investing/financing activities; overall cash burn persists.

🛡️ Balance Sheet & Liquidity

Total assets run around $11–12B with equity typically in the $6.8–9.4B range, and current assets above current liabilities (current ratio >1.5x–2x). Liabilities are modest relative to equity, supporting liquidity despite sustained negative cash flow.

⚠️ Key Drivers & Risks

• Drivers: mRNA vaccine/therapeutics development and commercialization; continued platform leverage for vaccines.
• Risks: revenue/earnings volatility and cash burn; regulatory and competitive dynamics affecting pipeline and pricing.